23 min
September 2021: Aducanumab for Alzheimer’s, antibiotics, shared-decision making, and dental health DTB Podcast
-
- Medicine
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the September issue of DTB. They discuss the US FDA's controversial decision to license aducanumab for Alzheimer's disease (https://dtb.bmj.com/content/59/9/130) and consider barriers to prescribing shorter courses of antibiotics in primary care (https://dtb.bmj.com/content/59/9/131). The editors also highlight the impact that some medicines have on oral health and dental treatment (https://dtb.bmj.com/content/59/9/135).
Before all of that though, the recent NICE's guideline on shared decision making.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the September issue of DTB. They discuss the US FDA's controversial decision to license aducanumab for Alzheimer's disease (https://dtb.bmj.com/content/59/9/130) and consider barriers to prescribing shorter courses of antibiotics in primary care (https://dtb.bmj.com/content/59/9/131). The editors also highlight the impact that some medicines have on oral health and dental treatment (https://dtb.bmj.com/content/59/9/135).
Before all of that though, the recent NICE's guideline on shared decision making.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
23 min